Artemether ameliorates adriamycin induced cardiac atrophy in mice

Weng,Wenci; Yu,Xuewen; Dong,Yifan; Wang,Taifen; Shao,Mumin; Sun,Huili; Han,Pengxun

doi:10.3892/mmr.2023.13040

Artemether ameliorates adriamycin induced cardiac atrophy in mice

Authors:
- Wenci Weng
- Xuewen Yu
- Yifan Dong
- Taifen Wang
- Mumin Shao
- Huili Sun
- Pengxun Han
View Affiliations

Affiliations: Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Futian, Shenzhen, Guangdong 518033, P.R. China, Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Futian, Shenzhen, Guangdong 518033, P.R. China, Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Futian, Shenzhen, Guangdong 518033, P.R. China
Published online on: June 23, 2023 https://doi.org/10.3892/mmr.2023.13040
Article Number: 153
Copyright: © Weng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adriamycin is a widely used and effective antitumor drug; however, its application is limited by various side effects, including irreversible cardiotoxicity. The central role of cardiac atrophy in Adriamycin‑induced cardiotoxicity has been revealed; however, the underlying mechanism of this process remains unclear. Artemether is a well‑known Chinese herbal medicine, and its pharmacological action is related to the regulation of mitochondrial function and redox status. The present study determined the effects of artemether on Adriamycin‑induced cardiotoxicity and investigated the underlying mechanisms. After mouse model establishment and artemether intervention, experimental methods including pathological staining, immunohistochemistry, immunofluorescence, immunoblotting, ELISA and reverse transcription‑quantitative PCR were used to evaluate the therapeutic effect. The results demonstrated that artemether prevented Adriamycin‑induced cardiac atrophy and recovered the intercombination of connexin 43 and N‑cadherin at the intercalated discs. Artemether also regulated the autophagy pathway and restored the unbalanced ratio of Bax and Bcl‑2 in myocardial cells. In addition, the increased serum H2O2 levels after Adriamycin exposure were significantly decreased by artemether, and the mitochondrial alterations and redox imbalance in myocardial cells were also improved to varying degrees. In summary, the findings of the present study provide reliable evidence that artemether could ameliorate cardiac atrophy induced by Adriamycin. This therapeutic approach may be translated to the clinic for preventing drug‑induced heart diseases.

View Figures

View References

1	van der Zanden SY, Qiao X and Neefjes J: New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 288:6095–6111. 2021. View Article : Google Scholar : PubMed/NCBI
2	Tacar O, Sriamornsak P and Dass CR: Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sritharan S and Sivalingam N: A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278:1195272021. View Article : Google Scholar : PubMed/NCBI
4	Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA and Karuppusamy I: Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 200:26–30. 2018. View Article : Google Scholar : PubMed/NCBI
5	Christidi E and Brunham LR: Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 12:3392021. View Article : Google Scholar : PubMed/NCBI
6	Chen DS, Yan J and Yang PZ: Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity. Front Cardiovasc Med. 9:8125782022. View Article : Google Scholar : PubMed/NCBI
7	Ferreira de Souza T, Quinaglia AC, Silva T, Osorio Costa F, Shah R, Neilan TG, Velloso L, Nadruz W, Brenelli F, Sposito AC, Matos-Souza JR, et al: Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 11:1045–1055. 2018. View Article : Google Scholar : PubMed/NCBI
8	Bartlett JJ, Trivedi PC and Pulinilkunnil T: Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 104:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
9	Willis MS, Parry TL, Brown DI, Mota RI, Huang W, Beak JY, Sola M, Zhou C, Hicks ST, Caughey MC, et al: Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1. Circ Heart Fail. 12:e0052342019. View Article : Google Scholar : PubMed/NCBI
10	Ma N, Zhang Z, Liao F, Jiang T and Tu Y: The birth of artemisinin. Pharmacol Ther. 216:1076582020. View Article : Google Scholar : PubMed/NCBI
11	Esu EB, Effa EE, Opie ON and Meremikwu MM: Artemether for severe malaria. Cochrane Database Syst Rev. 6:CD0106782019.PubMed/NCBI
12	Wang Y, Wang Y, You F and Xue J: Novel use for old drugs: The emerging role of artemisinin and its derivatives in fibrosis. Pharmacol Res. 157:1048292020. View Article : Google Scholar : PubMed/NCBI
13	Dolivo D, Weathers P and Dominko T: Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics. Acta Pharm Sin B. 11:322–339. 2021. View Article : Google Scholar : PubMed/NCBI
14	Han P, Wang Y, Zhan H, Weng W, Yu X, Ge N, Wang W, Song G, Yi T, Li S, et al: Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice. Am J Transl Res. 11:1389–1402. 2019.PubMed/NCBI
15	Wang Y, Han P, Wang M, Weng W, Zhan H, Yu X, Yuan C, Shao M and Sun H: Artemether improves type 1 diabetic kidney disease by regulating mitochondrial function. Am J Transl Res. 11:3879–3889. 2019.PubMed/NCBI
16	Han P, Cai Y, Wang Y, Weng W, Chen Y, Wang M, Zhan H, Yu X, Wang T, Shao M and Sun H: Artemether ameliorates kidney injury by restoring redox imbalance and improving mitochondrial function in Adriamycin nephropathy in mice. Sci Rep. 11:12662021. View Article : Google Scholar : PubMed/NCBI
17	Cheng X, Zhou P, Weng W, Sun Z, Liu H, Chen Y, Cai Y, Yu X, Wang T, Shao M, et al: Artemether attenuates renal tubular injury by targeting mitochondria in adriamycin nephropathy mice. Am J Transl Res. 14:2002–2012. 2022.PubMed/NCBI
18	Weng W, Liu H, Sun Z, Zhou P, Yu X, Shao M, Han P and Sun H: Combined treatment with niclosamide ethanolamine and artemether combination improves type 1 diabetes via the targeting of liver mitochondria. Exp Ther Med. 23:2392022. View Article : Google Scholar : PubMed/NCBI
19	Wallace KB, Sardao VA and Oliveira PJ: Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 126:926–941. 2020. View Article : Google Scholar : PubMed/NCBI
20	Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML and Lakatta EG: Use of tibial length to quantify cardiac hypertrophy: Application in the aging rat. Am J Physiol. 243:H941–H947. 1982.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zhao G, Qiu Y, Zhang HM and Yang D: Intercalated discs: Cellular adhesion and signaling in heart health and diseases. Heart Fail Rev. 24:115–132. 2019. View Article : Google Scholar : PubMed/NCBI
23	Leo-Macias A, Agullo-Pascual E and Delmar M: The cardiac connexome: Non-canonical functions of connexin43 and their role in cardiac arrhythmias. Semin Cell Dev Biol. 50:13–21. 2016. View Article : Google Scholar : PubMed/NCBI
24	Orogo AM and Gustafsson AB: Therapeutic targeting of autophagy: Potential and concerns in treating cardiovascular disease. Circ Res. 116:489–503. 2015. View Article : Google Scholar : PubMed/NCBI
25	Gross A and Katz SG: Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 24:1348–1358. 2017. View Article : Google Scholar : PubMed/NCBI
26	Chong SJF, Marchi S, Petroni G, Kroemer G, Galluzzi L and Pervaiz S: Noncanonical cell fate regulation by Bcl-2 Proteins. Trends Cell Biol. 30:537–555. 2020. View Article : Google Scholar : PubMed/NCBI
27	Jang S and Javadov S: OPA1 regulates respiratory supercomplexes assembly: The role of mitochondrial swelling. Mitochondrion. 51:30–39. 2020. View Article : Google Scholar : PubMed/NCBI
28	Dan Dunn J, Alvarez LA, Zhang X and Soldati T: Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol. 6:472–485. 2015. View Article : Google Scholar : PubMed/NCBI
29	Shimauchi T, Numaga-Tomita T, Ito T, Nishimura A, Matsukane R, Oda S, Hoka S, Ide T, Koitabashi N, Uchida K, et al: TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight. 2:e933582017. View Article : Google Scholar : PubMed/NCBI
30	Nash PL: Brain type natriuretic peptide. Neonatal Netw. 27:343–346. 2008. View Article : Google Scholar : PubMed/NCBI
31	Belardi B, Son S, Felce JH, Dustin ML and Fletcher DA: Cell-cell interfaces as specialized compartments directing cell function. Nat Rev Mol Cell Biol. 21:750–764. 2020. View Article : Google Scholar : PubMed/NCBI
32	Dikic I and Elazar Z: Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 19:349–364. 2018. View Article : Google Scholar : PubMed/NCBI
33	Montalvo RN, Doerr V, Min K, Szeto HH and Smuder AJ: Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 318:R227–R233. 2020. View Article : Google Scholar : PubMed/NCBI
34	Wang Y, Branicky R, Noe A and Hekimi S: Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol. 217:1915–1928. 2018. View Article : Google Scholar : PubMed/NCBI
35	Boyd SD, Ullrich MS, Skopp A and Winkler DD: Copper Sources for Sod1 Activation. Antioxidants (Basel). 9:5002020. View Article : Google Scholar : PubMed/NCBI
36	Papa L, Hahn M, Marsh EL, Evans BS and Germain D: SOD2 to SOD1 switch in breast cancer. J Biol Chem. 289:5412–5416. 2014. View Article : Google Scholar : PubMed/NCBI
37	Chang YC, Fong Y, Tsai EM, Chang YG, Chou HL, Wu CY, Teng YN, Liu TC, Yuan SS and Chiu CC: Exogenous C₈-Ceramide induces apoptosis by overproduction of ROS and the switch of superoxide dismutases SOD1 to SOD2 in human lung cancer cells. Int J Mol Sci. 19:30102018. View Article : Google Scholar : PubMed/NCBI